Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1667523

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Osteoporosis: Romosozumab
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has a planned timescale for when romosozumab will be available in the NHS for the treatment of Osteoporosis.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	222
answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended by NICE, usually within three months of final guidance.</p><p>NICE published guidance in May 2022 recommending romosozumab for treating severe osteoporosis in people after menopause who are at high risk of fracture. Romosozumab is therefore available for clinicians to prescribe to NHS patients who meet the specified criteria, in line with NICE’s recommendations.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 10:25:40 answering member 4423 label Biography information for Will Quince
tabling member	4131 label Biography information for Jim Shannon

1668018

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Abiraterone
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will review the decision to reject the use of the drug Abiraterone to tackle prostate cancer.
tabling member constituency	Richmond Park
tabling member printed	Sarah Olney
uin	377
answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that guides the National Health Service on funding new medicines, based on clinical and cost-effectiveness.. The NHS is legally required to fund medicines recommended by NICE, usually within 3 months of final guidance.</p><p>NICE has recommended abiraterone for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone in line with NICE’s recommendations, ensuring access for eligible patients.</p><p>Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is currently considering a clinical policy proposal for abiraterone as a treatment option for potential use in specific cases. The proposal is due to be discussed later this month, with potential stakeholder testing by January 2024, if supported.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 11:00:41 answering member 4423 label Biography information for Will Quince
tabling member	4591 label Biography information for Sarah Olney

1666862

registered interest
date	24/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answers of 16 October 2023 to Questions 200120, 200121, 200122 and 200123 on Medial Treatments: Innovation, which criteria within the MedTech Strategy Programme governance structures will be used to assess the range of initiatives.
tabling member constituency	Dewsbury
tabling member printed	Mark Eastwood
uin	204055
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to respond to the hon. Member in the time available before Prorogation.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:59:38 answering member 4423 label Biography information for Will Quince
tabling member	4807 label Biography information for Mark Eastwood

1666503

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ovarian Cancer: Health Education
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will launch an awareness campaign on abdominal and urological symptoms of ovarian cancer.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	203763
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>NHS England is currently running a ‘Help us Help you’ campaign highlighting the abdominal and urological symptoms of cancer, including ovarian cancer, and addressing the barriers that stop people from accessing services in the National Health Service.</p><p>It encourages the public to contact their general practitioner if they're worried about symptoms, such as “tummy discomfort or diarrhoea that lasts for three weeks or more, or if they've seen blood in their pee even once”.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:50:31 answering member 4423 label Biography information for Will Quince
tabling member	1409 label Biography information for Mr Gregory Campbell

1666537

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 September 2023 to Question 198889 on Genomics: Health Services, if he will list the companies (a) involved in delivering and (b) that provided technology and products in support of the NHS Genomic Medicine Service.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	203889
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to reply to the hon. Member in the time available before prorogation.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 09:40:05 answering member 4423 label Biography information for Will Quince
tabling member	4523 label Biography information for Catherine West

1666549

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure the Major Conditions Strategy reflects the (a) views and (b) needs of people with lived experience of cancer as a young adult.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	203755
answer	answer is ministerial correction date of answer 25/10/2023 answer text <p>Cancer is a priority for this Government and the Department continues to take steps to demonstrate this. Childhood, young people’s and young adults’ cancers are included within the Department’s Major Conditions Strategy, which tackles contributions contributing most to morbidity and mortality.</p><p>While the Department cannot pre-empt its outcomes, the Major Conditions Strategy’s final report scheduled for early 2024 will draw on previous work, including submissions from childhood, young people and young adults’ cancer charities and stakeholders in response to our calls for evidence on cancer and on major conditions. The emphasis is on earlier diagnosis, better support to manage conditions, and improved coordination of treatment and care.</p><p>The Department is engaging with several stakeholders in the development of the Major Conditions Strategy including organisations that represent the needs and care of people with lived experience of cancer.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203756 question first answered 25/10/2023 12:08:34 answering member 4423 label Biography information for Will Quince
tabling member	481 label Biography information for Sir George Howarth

1666550

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how the Major Conditions Strategy will take into account the (a) care and (b) support needs of teenagers and young adults with cancer.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	203756
answer	answer is ministerial correction date of answer 25/10/2023 answer text <p>Cancer is a priority for this Government and the Department continues to take steps to demonstrate this. Childhood, young people’s and young adults’ cancers are included within the Department’s Major Conditions Strategy, which tackles contributions contributing most to morbidity and mortality.</p><p>While the Department cannot pre-empt its outcomes, the Major Conditions Strategy’s final report scheduled for early 2024 will draw on previous work, including submissions from childhood, young people and young adults’ cancer charities and stakeholders in response to our calls for evidence on cancer and on major conditions. The emphasis is on earlier diagnosis, better support to manage conditions, and improved coordination of treatment and care.</p><p>The Department is engaging with several stakeholders in the development of the Major Conditions Strategy including organisations that represent the needs and care of people with lived experience of cancer.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203755 question first answered 25/10/2023 12:08:34 answering member 4423 label Biography information for Will Quince
tabling member	481 label Biography information for Sir George Howarth

1666551

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve data reporting on the (a) outcomes and (b) experiences of young people with cancer.
tabling member constituency	Knowsley
tabling member printed	Sir George Howarth
uin	203757
answer	answer is ministerial correction date of answer 25/10/2023 answer text <p>The Department is taking steps, along with other organisations, to better understand data on outcomes and experiences of young people with cancer.</p><p>On the data reporting of outcomes, the National Cancer Registration and Analysis Service (NCRAS) collects, quality assures and analyses data on all people living in England who are diagnosed with cancer, including young people.</p><p>This data is used to measure diagnosis, treatment and outcomes for patients diagnosed with cancer. The data held by NCRAS supports service provision and commissioning in the National Health Service, clinical audits, and public health and epidemiological research, all of which contribute to improved outcomes for those diagnosed with cancer.</p><p>The National Cancer Patient Experience Survey, commissioned by NHS England, aims to understand the experiences of cancer care across England, for all patients aged 16 years old or over. This has surveyed patients annually since 2010.</p><p>In addition, the Under 16 Cancer Patient Experience Survey, commissioned by NHS England, is now in its second year and aims to gather feedback from children and young people and their parents/carers on the cancer care and treatment received.</p><p>These surveys provide valuable findings, helping the NHS to understand what is good about children, young people’s and adults’ cancer care, and identifying areas for improvements.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/10/2023 12:10:10 answering member 4423 label Biography information for Will Quince
tabling member	481 label Biography information for Sir George Howarth

1666571

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Members: Correspondence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when he plans to reply to the letters of (a) 21 August and (b) 19 September 2023 from the hon. Member for Weston-super-Mare on the availability of Ethypharm.
tabling member constituency	Weston-super-Mare
tabling member printed	John Penrose
uin	203792
answer	answer is ministerial correction date of answer 25/10/2023 answer text <p>I replied to the hon. Member on 2 October 2023.</p> answering member constituency Colchester answering member printed Will Quince question first answered 25/10/2023 13:45:15 answering member 4423 label Biography information for Will Quince
tabling member	1584 label Biography information for John Penrose

1666582

registered interest
date	23/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that alternatives to elvanse and guanfacine are available for people with ADHD.
tabling member constituency	Southport
tabling member printed	Damien Moore
uin	203938
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), including elvanse and guanfacine. Some issues have now been resolved. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. These issues are expected to resolve by the end of December 2023.</p><p>We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p><p>We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 203939 question first answered 26/10/2023 06:15:56 answering member 4423 label Biography information for Will Quince
tabling member	4669 label Biography information for Damien Moore